| Vikram A Kumar, MD | |
|
1331 N 7th St Ste 405, Phoenix, AZ 85006-2754 | |
| (866) 974-2673 | |
| (866) 939-2673 |
| Full Name | Vikram A Kumar |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 24 Years |
| Location | 1331 N 7th St Ste 405, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295758035 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 35612 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Banner - University Medical Center Phoenix | Phoenix, AZ | Hospital |
| Core Institute Specialty Hospital, The | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Center For Orthopedic Research And Education Llc | 0345287322 | 236 |
News Archive
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
Early life exposure to normal bacteria of the GI tract (gut microbes) protects against autoimmune disease in mice, according to research published on-line in the January 17 edition of Science. The study may also have uncovered reasons why females are at greater risk of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and lupus compared to males.
Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.
AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
› Verified 5 days ago
| Entity Name | Center For Orthopedic Research And Education Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427095801 PECOS PAC ID: 0345287322 Enrollment ID: O20050412000087 |
News Archive
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
Early life exposure to normal bacteria of the GI tract (gut microbes) protects against autoimmune disease in mice, according to research published on-line in the January 17 edition of Science. The study may also have uncovered reasons why females are at greater risk of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and lupus compared to males.
Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.
AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
› Verified 5 days ago
| Entity Name | Arizona Neurosurgery And Spine Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083801054 PECOS PAC ID: 3870681695 Enrollment ID: O20071113000159 |
News Archive
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
Early life exposure to normal bacteria of the GI tract (gut microbes) protects against autoimmune disease in mice, according to research published on-line in the January 17 edition of Science. The study may also have uncovered reasons why females are at greater risk of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and lupus compared to males.
Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.
AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
› Verified 5 days ago
| Entity Name | Northern Arizona Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669914552 PECOS PAC ID: 3577473362 Enrollment ID: O20170801003409 |
News Archive
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
Early life exposure to normal bacteria of the GI tract (gut microbes) protects against autoimmune disease in mice, according to research published on-line in the January 17 edition of Science. The study may also have uncovered reasons why females are at greater risk of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and lupus compared to males.
Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.
AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vikram A Kumar, MD 18444 N 25th Ave Ste 310, Phoenix, AZ 85023-1266 Ph: (866) 974-2673 | Vikram A Kumar, MD 1331 N 7th St Ste 405, Phoenix, AZ 85006-2754 Ph: (866) 974-2673 |
News Archive
Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.
Early life exposure to normal bacteria of the GI tract (gut microbes) protects against autoimmune disease in mice, according to research published on-line in the January 17 edition of Science. The study may also have uncovered reasons why females are at greater risk of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and lupus compared to males.
Researchers on Monday announced they were calling off a trial to test whether taking an oral HIV drug reduces the risk of HIV infection in women after interim analysis of the study showed women taking the medication were no less likely to become infected with HIV than those who were not taking the medicine, the Associated Press reports.
AbbVie, a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib.
› Verified 5 days ago
Curtis A Dickman, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2910 N 3rd Ave, Phoenix, AZ 85013 Phone: 602-406-3632 Fax: 602-406-4187 | |
Dr. Naresh P Patel, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
James Zhou, Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 350 W Thomas Rd, Phoenix, AZ 85013 Phone: 602-406-4958 | |
Dr. Mark Edward Oppenlander, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 19636 N 27th Ave Ste 203, Phoenix, AZ 85027 Phone: 235-625-0506 Fax: 623-562-5051 | |
Dr. Erik I Curtis, M.D., M.S. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2222 E Highland Ave Ste 222, Phoenix, AZ 85016 Phone: 602-603-0971 | |
Dr. Michael T Lawton, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave, Phoenix, AZ 85013 Phone: 602-406-3489 Fax: 602-406-4402 | |
Dr. Jonathan Seth Hott, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 9225 N 3rd St, Suite 100, Phoenix, AZ 85020 Phone: 602-943-4509 Fax: 602-943-0348 |